Roberto Nussenzveig

[UroToday.com @urotoday]

Genomic classifiers and AI for personalizing #ProstateCancer radiation therapy. @drjefstathiou @MassGenBrigham joins @neerajaiims @huntsmancancer to discuss the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. #WatchNow on UroToday > https://t.co/WSgUZx48Eg #APCCC26 @Decipher_VCYT @APCCC_Lugano @arteraAI

[Amanda Narod @AmandaBinDC]

Hello X! I'm back just in time to follow these colleagues ahead of #ASCO26. So excited to get some new folks into the mix!

[Sumanta K. Pal, MD, FASCO @montypal]

Leave it to @chadinabhan to pull together an exceptional group of faculty on Monday night at #ASCO26! Looking fwd to joining @DrRanaMcKay & @PGrivasMDPhD to discuss the latest developments in GU oncology - then, @VKaklamani, @stolaney1, #GregVidalMD & #JoyceOShaughnessyMD talk #breastcancer. Terrific faculty for GI, #lungcancer, #melanoma, & #braintumors as well - @DrSapnaPatel, @VivekSubbiah, @YJanjigianMD, @GIcancerDoc & so many more! Join us!

[Sumanta K. Pal, MD, FASCO @montypal]

Heading to #ASCO26? Have a listen to this podcast on your way. Was a real pleasure to sit down with #DrJoChien from @UCSFCancer (@ASCO Scientific Program Chair!) for a discussion of some fascinating abstracts, raning from #lungcancer screening to #diet/#exercise modification in #breastcancer to novel systemic therapy strategies for #GIST. @OncoAlert @DrChoueiri @neerajaiims @AlexisLeVee @NazliDizman @shilpaonc @hmcarthur

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial. To be Presented at #ASCO26

https://t.co/horHsN3BRN

Independent validation of the NADIR model in enzalutamide-treated patients from the 🏹ARCHES trial demonstrated strong performance in predicting early favorable PSA response in metastatic hormone-sensitive #ProstateCancer . The model achieved an AUC of 0.80 and effectively stratified patients by PSA response and overall survival. Patients in lower prediction tertiles experienced significantly worse survival outcomes. These findings support the NADIR model as a promising prognostic tool for patients receiving androgen receptor pathway inhibitor therapy.

@soumyajitroy @AarmstrongDuke @neerajaiims @DrRanaMcKay @AmarUKishan @PBarataMD @JasonBrownMDPhD @SpyrosBasourako @WallisCJD @DrSpratticus @NicholasZaorsky
Neal Shore ( @CURCMB )

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4502 @ASCO #ASCO26 by @DrChoueiri👉 https://t.co/SZg3hfw1wU👉ctDNA analysis from KEYNOTE-564 trial #kidneycancer👉ctDNA+ associated w/ worse DFS👉ctDNA clearance was higher in pembro arm👇@tompowles1 @OncoAlert @urotoday @kidneyCAN

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4500 @ASCO #ASCO26 by @DrRanaMcKay👉 https://t.co/gK1EwBuYWC👉Ph2 trial of Radium & Cabozantinib vs Cabo in RCC w/ bone mets #kidneycancer👉Radium did not improve SSE-free survival👉Novel RLT needed in RCC👇@DrChoueiri @ALLIANCE_org @OncoAlert @urotoday @kidneycan

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4520 @ASCO #ASCO26 by @PavlosMsaouel👉 https://t.co/uWJK7LTPE2👉Remarkable clinical activity of EGFR blockade (panitumumab) in SMARCB1-deficient renal medullary mRCC #kidneycancer👉Median PFS 5.8 mo & median OS 9.5 mo👇@NikiZacharias @BradMcG04 @OncoAlert @urotoday @kidneycan

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4519 @ASCO #ASCO26 by @RWinayak👉 https://t.co/jUT766TOBM👉Addition of CBM588 to ICB-based 1L combinations in mRCC #kidneycancer👉dysbiotic stool confers greater benefit & a potential biomarker👉Ph3 @SWOG BIOFRONT ongoing👇@montypal @nazlidizman @OncoAlert @urotoday @kidneycan

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4507 @ASCO #ASCO26 by @tompowles1 @shilpaonc👉https://t.co/fxlybBjl6j👉3.5 yr f/u of Ph3 EV-302 in aUC #bladdercancer👉42-month OS rate, 44% vs 24.6%; HR=0.53👉among pts w/ CR, 66% had initially PR👇 @OncoAlert @urotoday @uromigos @BladderCancerUS

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4513 @ASCO #ASCO26 by @RonaldChenMD👉 https://t.co/URhd9X5Y58👉Ph3 AMBASSADOR 👉Adj pembro vs observation after surgery in high risk MIUC #bladdercancer👉Adj pembro⬆️DFS without negatively affecting HRQoL👇@apolo_andrea @OncoAlert @urotoday @bladdercancerUS @ALLIANCE_org

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4514 @ASCO #ASCO26 by @shilpaonc👉 https://t.co/jAbQr5NsmT👉Ph3 trial of cabozantinib+avelumab vs avelumab after 1L platinum in aUC #bladdercancer 👉addition of cabo to Av did not improve OS or PFS👇@DrRosenbergMSK @OncoAlert @urotoday @bladdercancerUS @bergsa83

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4515 @ASCO #ASCO26 by @emanuele_crupi👉 https://t.co/nAA0Rgbb30👉Ph2 study of gemcitabine, 5-FU, and cisplatin (GemFLP) in advanced urinary tract adenoCa#bladdercancer👉44% ORR w/ durable response & baseline CA125 was associated w/ OS👇@OncoAlert @urotoday @bladdercancerUS

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#5004 @ASCO #ASCO26 by @AtishChoudhury👉 https://t.co/H6fxSyBYJB👉Ph2 de-escalation trial of Rx interruption in pts w/ mHSPC w/ PSA<0.2 ng/ml #prostatecancer👉41% remained Rx-free w/ testosterone recovery at 18 mo after Rx interruption👇 @OncoAlert @urotoday @PCF_science

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#5001 @ASCO #ASCO26 by @ChrisSweens1👉 https://t.co/u08U4HEinq👉Decipher Prostate Genomic Classifier (DGC) predicts benefit w/ triplet Rx in #prostatecancer👉DGC>0.85 is predictive of benefit from adding docetaxel to ADT+Enza👇@Prof_IanD @OncoAlert @urotoday @PCF_science

[Vivek Subbiah, MD @VivekSubbiah]

🚨Delighted to deliver a lecture at the #ASCO26 Clinical Science Symposium Session on one of the most exciting frontiers in sarcoma therapeutics @ASCO
🖖"To Boldly Deliver Where No Drug Has Gone Before: Antibody-Drug Conjugates in Sarcoma"
👉ADCs have transformed the treatment landscape across breast, lung, gastric, & urothelial cancers.
👉The question now, can we BOLDLY deliver this precision-guided payload paradigm to #sarcoma a family of >100+ rare + ultra-rare histologies long underserved by drug development?
👉Join us for a deep dive into the science, the targets, the trials, and what's next and amazing speakers.
🗓️ Monday, June 1, 2026 | 8:00–9:30 AM CDT
📍 Room S504, McCormick Place
⚠️ In-person only @OncoAlert @oncodaily @OpenMedicineHQ
🔗 https://t.co/yVW8nhd7St

[Rami Manochakian MD, FASCO @RManochakian]

🚨🔥@OncoAlert HOT OFF THE PRESS.

@ASCO Annual Meeting #ASCO26 #Abstracts JUST #RELEASED.

Looking forward & ready for:

⭐️GREAT

✅#Science
✅#Research
✅#Education
✅Practice Changing #Studies

🙏It’s an #EraOfHope for #Patients with #Cancer.

👇🏼
https://t.co/xq0SuQK3Fl

[UroToday.com @urotoday]

Longitudinal analysis of patient-reported outcomes in the PSMAddition trial. Michael Morris, MD @MSKCancerCenter joins @neerajaiims @huntsmancancer to discuss PSMAddition quality of life data showing lutetium-177 PSMA-617 plus ADT, and ARPI improved radiographic progression-free survival with a hazard ratio of 0.72. #WatchNow on UroToday > https://t.co/L3a9J01DCY

[Emanuele Crupi, MD @emanuele_crupi]

Grateful to the @urologysummit committee for the honor of serving as an #IUCS26 Ambassador.

THE Summit in GU you cannot miss

#SaveTheDate 3-4 September
Join in person in Guilford,UK, or online

Registration is FREE of cost

👉🏻https://t.co/b4VuMPIDE7

@gbanna74 @DrYukselUrun

[ASCO @ASCO]

🎙 Now that abstracts are released, @montypal of @cityofhope and Dr. Jo Chien of @UCSF preview several key studies being presented at #ASCO26 on a brand-new episode of the #ASCODailyNews Podcast: https://t.co/tym0DjLk9t